Sponsor or institution
Clinical trials and research at GC Biopharma Corp
As of November 12, 2026, Find a Trial lists 5 clinical trials run by GC Biopharma Corp that are recruiting, at sites in 4 countries (most in South Korea (4), Thailand (1), Argentina (1)). By phase: Phase 3 (2), Phase 1/2 (2), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 4Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| MG1111 (BARYCELA) versus VARIVAX for preventing chickenpox in children 1 to 12 years | Phase 3 | Khon Kaen, Changwat Khon Kaen | Recruiting | Jul 8, 2025 |
| GC3111B versus Boostrix® as a Tdap booster in healthy adults | Phase 1/2 | Seoul | Recruiting | May 30, 2025 |
| Testing HM15421 (GC1134A) for safety and tolerability in people with Fabry disease | Phase 1/2 | Los Angeles, California and 9 other locations | Recruiting | Mar 5, 2025 |
| Evaluating the safety and effectiveness of I.V.-Hepabig for post-liver transplant patients with Hepatitis B | Phase 3 | Goyang-si, Gyeonggi-do and 7 other locations | Recruiting | Jan 17, 2023 |
| Evaluating a second varicella vaccination in young children | Phase 2 | Ansan | Recruiting | Jun 16, 2022 |
All recruiting trials (5)
-
MG1111 (BARYCELA) versus VARIVAX for preventing chickenpox in children 1 to 12 years
This will test whether the MG1111 (BARYCELA) vaccine is safe and produces an immune response comparable to VARIVAX in healthy children aged 12 months to 12 years.
-
GC3111B versus Boostrix® as a Tdap booster in healthy adults
This study will test whether the GC3111B vaccine is safe and produces protective immune responses comparable to Boostrix® when given as a Tdap booster to healthy adults aged 19–64.
-
Testing HM15421 (GC1134A) for safety and tolerability in people with Fabry disease
This Phase 1/2 study will test whether HM15421 (GC1134A) is safe and well tolerated in adults with Fabry disease and will collect early data on how the drug behaves in the body and affects disease markers.
-
Evaluating the safety and effectiveness of I.V.-Hepabig for post-liver transplant patients with Hepatitis B
This study tests if a new treatment called I.V.-Hepabig can safely help liver transplant patients who had Hepatitis B by preventing the virus from coming back.
-
Evaluating a second varicella vaccination in young children
This study is testing a second chickenpox vaccine in healthy kids aged 4 to 6 to see if it's safe and helps boost their immunity after they’ve already had the first shot.
Quick answers
How many clinical trials run by GC Biopharma Corp are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in South Korea (4 trials), Thailand (1 trial), Argentina (1 trial), United States (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 1/2: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.